Riskpilot← Back to searchSign inGet full accessNeo Coating Pharma ApS
APSActiveCVR 28668570Høffdingsvej 34Construction of residential and non-residential buildings · NACE 4100Est. 20063 employees
Revenue 2025
DKK -38K
-108% vs 2024
EBITDA margin
100.0%
+74% vs 2024
Equity ratio
95.1%
Financial strength
Net profit 2025
DKK -29K
+78% vs 2024
| Revenue | DKK -38K | -108% |
| EBITDA | DKK -38K | +74% |
| Net profit | DKK -29K | +78% |
| Total assets | DKK 457K | -7% |
| Equity | DKK 434K | -6% |
| Employees | 3 | — |
Legal name
Neo Coating Pharma ApS
CVR number
28668570
Legal form
Anpartsselskab
NACE code
4100 · Construction of residential and non-residential buildings
Founded
8. november 2006
Share capital
DKK 150.000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-06-30
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør og et bestyrelsesmedlem, eller af to bestyrelsesmedlemmer.
Company purpose
Selskabets formål er at drive entreprenør virksomhed i bred forstand.
Address
Høffdingsvej 34
Email
tommy@tscoating.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.684 | 1.969 | 1.427 | 1.644 | 2.875 | 2.225 | 1.944 | 1.669 | 3.323 | 2.992 | 2.250 | 489 | -38 |
| Staff expenses | -1.555 | -1.600 | -1.478 | -1.582 | -1.800 | -1.555 | -1.506 | -1.505 | -2.064 | -2.052 | -2.084 | -637 | -0 |
| EBITDA | 129 | 430 | -51 | 62 | 1.075 | 669 | 439 | 164 | 1.259 | 941 | 165 | -148 | -38 |
| Depreciation & amort. | 73 | -14 | -0 | -0 | -0 | -0 | -1 | -18 | -18 | -18 | -18 | -16 | -0 |
| EBIT | 56 | 415 | -51 | 62 | 1.075 | 669 | 437 | 146 | 1.241 | 923 | 147 | -165 | -38 |
| Net financials | -1 | -2 | 12 | -2 | -2 | -7 | -22 | -24 | -32 | -18 | -12 | -0 | 0 |
| Profit before tax | 56 | 414 | -40 | 60 | 1.073 | 663 | 416 | 122 | 1.209 | 905 | 135 | -165 | -38 |
| Tax | -26 | 145 | -9 | 15 | 238 | 146 | 92 | 26 | 267 | 200 | 30 | -31 | -8 |
| Net profit | 82 | 269 | -31 | 45 | 835 | 517 | 324 | 96 | 942 | 705 | 105 | -133 | -29 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 870 | 1.409 | 946 | 1.147 | 2.163 | 1.865 | 1.832 | 1.683 | 3.502 | 2.818 | 1.123 | 492 | 457 |
| Equity | 600 | 870 | 639 | 684 | 1.519 | 835 | 659 | 455 | 1.397 | 1.702 | 207 | 464 | 434 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 270 | 539 | 307 | 464 | 644 | 1.029 | 1.162 | 1.220 | 2.096 | 1.109 | 911 | 28 | 23 |
| Total debt | 270 | 539 | 307 | 464 | 644 | 1.029 | 1.162 | 1.220 | 2.096 | 1.109 | 911 | 28 | 23 |
EBITDA margin
-3781100.0%
This company
15.8%
Market median
-23931113% vs market
20122025
Equity ratio
95.1%
This company
38.2%
Market median
+149% vs market
20122025
Return on equity
-6.7%
This company
18.4%
Market median
-136% vs market
20122025
Net profit margin
-2932000.0%
This company
8.1%
Market median
-36197631% vs market
20122025
Asset turnover
-0.08×
This company
1.12×
Market median
-107% vs market
20122025
Debt / equity
0.05×
This company
0.62×
Market median
+92% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via CVR / Virk · Period 2023-01-01 – 2024-06-30
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TK Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
JK Management | Management | 2023 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2024 | — | — | |
| Chairman | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Cortus A/S | Company | 100.0% | 100.0% | 2023 |
| Individual | 100.0% | 100.0% | 2006 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Silvis Holding ApS
Neo Coating Pharma ApS Board members of Neo Coating Pharma ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Thomas Kjeldgård Nielsen | Chief Executive Officer | 0 companies |
| Jimmy Kahl | Management | 0 companies |
| Christian Rossen Jeppesen | Board of Directors | 0 companies |
| Morten Kragh-Sørensen | Chairman | 0 companies |